TrialDiabetes, obesity & metabolism2021

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide.

Michele Schiavon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.